Skip to main content
Fig. 9 | Molecular Neurodegeneration

Fig. 9

From: Behavioral and neural network abnormalities in human APP transgenic mice resemble those of App knock-in mice and are modulated by familial Alzheimer’s disease mutations but not by inhibition of BACE1

Fig. 9

Early BACEi treatment does not prevent NaV1.1 depletion in J20 mice. a–d J20 mice (+) and WT controls (−) were treated with the BACEi NB-360 (+) or placebo (−) starting at 1 month of age. NaV1.1 and NaV1.6 levels in the parietal cortex were determined by western blot analysis at 7–9 months of age. a, b Images of western blots depicting signals for NaV1.1 (a) and NaV1.6 (b). GAPDH served as a loading control. c, d Quantitation of relative NaV1.1 (c) and NaV1.6 (d) levels. Average levels in placebo-treated WT mice were arbitrarily defined as 1.0. n = 8–16 female mice per group. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 vs. placebo-treated WT mice or as indicated by brackets, based on multiple Welch t-tests (c) or one-way ANOVA (d) with Holm-Sidak correction. Values are means ± SEM

Back to article page

Molecular Neurodegeneration

ISSN: 1750-1326